SOURCE: Health Enhancement Products, Inc

November 03, 2011 08:30 ET

Health Enhancement Products, Inc. Appoints New Chief Financial Officer

SCOTTSDALE, AZ--(Marketwire - Nov 3, 2011) - The board directors of Health Enhancement Products, Inc. (OTCBB: HEPI) a Scottsdale, AZ based food ingredients and nutraceutical enterprise, has appointed Philip M. Rice, II as Chief Financial Officer. Mr. Rice is managing principal and founder of Legacy Results, a Michigan-based consulting firm. Prior to founding Legacy Results in 2001, Mr. Rice served as Chief Operating Officer of Stahl's Inc., Chief Financial Officer of Gallagher-Kaiser Corp., and President and CFO of Speedy International, Inc.

Philip Rice began his professional career at Deloitte & Touche where he became a Certified Public Accountant (CPA) in 1979. He has facilitated business transactions in North America, Europe, Asia, Central and South America for various private and publicly-held corporations.

Mr. Rice serves on several private company advisory boards and is a member of the Michigan Association of CPAs and the American Institute of CPAs.

"We are pleased that Phil Rice has accepted this position," states board chairman Stephen Warner. "He will no doubt bring great value and credibility to the Company as he institutes more sophisticated financial controls and reporting. We are eager to move forward with plans to recast the organizational structure of HEPI in advance of expected growth in scope and revenues."

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCBB: HEPI) is a health & wellness company engaged in the development of a product comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme® (PAZ™), a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme®.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

Contact Information

  • IR Contact:

    David Sasso